#ESCCongress – [Abstract Only] Randomized trial: Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet

Commentary: EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class – TCTMD

Commentary on Twitter

Latebreaking now at #ESCCongress—Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial https://t.co/JcJnGI0VVt pic.twitter.com/Xmf98Bcoir

— The Lancet (@TheLancet) August 29, 2020